OrsoBio obesity data; Monte Rosa’s prostate cancer pill; Development pacts for Adaptive and SandboxAQnews2025-12-16T16:02:42+00:00December 16th, 2025|Endpoints News|
Innovent’s obesity drug data in adolescents; Everest gets rights to PCSK9 inhibitornews2025-12-12T14:36:09+00:00December 12th, 2025|Endpoints News|
Corbus’ obesity pill posts muted weight loss data; Disco adds another €16M in seed fundingnews2025-12-11T15:15:16+00:00December 11th, 2025|Endpoints News|
J&J joins ‘menin party’ at ASH; GSK to work with Oxford BioTherapeuticsnews2025-12-10T15:34:26+00:00December 10th, 2025|Endpoints News|
Stealthy biotech Sidera Bio raises $109M; Assembly’s data for oral herpes drugsnews2025-12-09T15:54:43+00:00December 9th, 2025|Endpoints News|
Day One was one of three parties interested in Mersana; Bihua Chen and Cormorant’s third SPACnews2025-12-08T15:50:56+00:00December 8th, 2025|Endpoints News|
Denali drug hold; Intercept layoffs; Capital raises for Immatics, Capricor and Protaranews2025-12-05T16:05:30+00:00December 5th, 2025|Endpoints News|
UniQure restates FDA’s negative feedback on Huntington’s trial; Neurimmune’s expanded AstraZeneca alliancenews2025-12-04T15:06:59+00:00December 4th, 2025|Endpoints News|
Orion’s €180M milestone payment; Iolyx partners dry eye candidatenews2025-12-03T15:28:34+00:00December 3rd, 2025|Endpoints News|
Pfizer culls ulcerative colitis candidate; Tiziana to try spinning out IL-6 drugnews2025-12-02T15:46:30+00:00December 2nd, 2025|Endpoints News|
